Rituximab maintenance in follicular lymphoma patients

Table 3 Randomized trials comparing rituximab maintenance vs observation after chemotherapy or immunochemotherapy

Reference	Year	Prior treatment	Maintenance schedule	No. of pts	Median F-up	PFS	OS
Hochster et al[17]	2009	CVP (1st line)	R x 4 (weekly) every 6 mo x 4 vs observation	228	3.7 years	Median: 4.3 vs 1.3 years; At 3 years: 64% vs 33% ( P < 0.001)	At 3 years: 91% vs 86% (P = 0.08)
Forstpointner et al[10]	2006	FCM or R-FCM (relapsed disease)	R x 4 (weekly) every 6 mo x 2 vs observation	105	26 mo	Median: Not reached vs 16 mo (P < 0.001)	At 3 years (estimated): 77% vs 57% (P = 0.1)
van Oers et al[6,7]	20062010	CHOP or R-CHOP (relapsed disease)	R every 3 mo x 8 vs observation	334	6 years	Median: 3.7 vs 1.3 years; At 3 years: 59% vs 28% (P < 0.001)	At 5 years: 74% vs 64% (P = 0.07)
Salles et al[18,23]	2010	R-CHOP, R-CVP, R-FCM (1st line)	R every 2 mo x 12 vs observation	1018	25 mo	At 2 years: 79% vs 60% (P < 0.001)	At 2 years: NS